Analyst Price Targets — AARD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 15, 2026 8:42 am | — | Morgan Stanley | $3.00 | $6.73 | TheFly | Aardvark downgraded to Underweight from Equal Weight at Morgan Stanley |
| March 2, 2026 5:41 am | Brian Abrahams | RBC Capital | $6.00 | $12.49 | StreetInsider | RBC Capital Downgrades Aardvark Therapeutics Inc (AARD) to Sector Perform |
| January 12, 2026 9:47 am | Chris Raymond | Raymond James | $47.00 | $14.27 | StreetInsider | Raymond James Reiterates Strong Buy Rating on Aardvark Therapeutics Inc (AARD) |
| December 23, 2025 11:23 am | Leland Gershell | Oppenheimer | $35.00 | $14.55 | TheFly | Aardvark Therapeutics initiated with an Outperform at Oppenheimer |
| November 14, 2025 9:30 am | Brian Abrahams | RBC Capital | $18.00 | $10.86 | StreetInsider | Aardvark Therapeutics Inc (AARD) PT Lowered to $18 at RBC Capital |
| September 29, 2025 8:43 am | — | Stifel Nicolaus | $24.00 | $13.23 | TheFly | Aardvark Therapeutics initiated with a Buy at Stifel |
| March 10, 2025 8:53 am | — | Morgan Stanley | $29.00 | $9.98 | TheFly | Aardvark Therapeutics initiated with an Overweight at Morgan Stanley |
Latest News for AARD
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK,
NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February…
New York, New York--(Newsfile Corp. - September 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii)…
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) and certain officers and directors. The class action, filed in the United States District Court for the Southern District of California, and docketed under 26-cv-04643, is on behalf of a class consisting of all persons and…
LOS ANGELES, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 13, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) securities between February 10, 2025 and May 14, 2026 inclusive (the “Class Period”).
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AARD.
U.S. House Trading
No House trades found for AARD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.